Intuitive Surgical Reports Higher 2Q Profit, Sales
By Grace Yoon
Intuitive Surgical logged higher profit in its second quarter, as sales increased.
The maker of robotic surgery systems on Thursday posted net income of $818.1 million, or $2.29 a share, compared with $658.4 million, or $1.81 a share, a year earlier.
Adjusted earnings were $2.80 a share. Analysts polled by FactSet expected $2.51 a share.
Revenue rose 19% to $2.89 billion, compared with analyst expectations for $2.82 billion. The increase in sales was driven by growth in procedure volume, higher da Vinci system leasing revenue and an increase in the installed base of da Vinci and Ion systems, the company said.
Intuitive forecast worldwide da Vinci procedure growth of approximately between 14% and 15%.
The company placed 468 da Vinci surgical systems compared with 395 a year before.
Competition in the surgical robots market continues to ramp up. Stryker launched its Mako robotic power system for total knee replacement procedures in the U.S. commercially earlier Thursday. Medtronic is seeking U.S. regulatory approval to expand the uses of its Hugo robotic-assisted survey system to include general surgery and gynecologic procedures.
Write to Grace Yoon at grace.yoon@wsj.com
(END) Dow Jones Newswires
July 16, 2026 16:56 ET (20:56 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
